John C. Thomas - 01 Mar 2026 Form 3 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
EVP, General Counsel
Signature
/s/ John C. Thomas
Issuer symbol
KRYS
Transactions as of
01 Mar 2026
Net transactions value
$0
Form type
3
Filing time
06 Mar 2026, 18:24:44 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Thomas John Charles EVP, General Counsel C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH /s/ John C. Thomas 06 Mar 2026 0002114900

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KRYS Common Stock 642 01 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KRYS Stock Option (Right to Buy) 01 Mar 2026 Common Stock 9,050 $275.64 Direct F1
holding KRYS Restricted Stock Units 01 Mar 2026 Common Stock 3,628 Direct F2, F3, F4
holding KRYS Stock Option (Right to Buy) 01 Mar 2026 Common Stock 7,500 $179.25 Direct F5
holding KRYS Restricted Stock Units 01 Mar 2026 Common Stock 835 Direct F3, F4, F6
holding KRYS Stock Option (Right to Buy) 01 Mar 2026 Common Stock 2,860 $159.47 Direct F7
holding KRYS Restricted Stock Units 01 Mar 2026 Common Stock 1,250 Direct F4, F8
holding KRYS Stock Option (Right to Buy) 01 Mar 2026 Common Stock 8,650 $81.91 Direct F9
holding KRYS Stock Option (Right to Buy) 01 Mar 2026 Common Stock 1,350 $63.55 Direct F10
holding KRYS Stock Option (Right to Buy) 01 Mar 2026 Common Stock 32,400 $52.21 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option was granted on February 27, 2026, and vests in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F2 The restricted stock units ("RSUs") vest in four equal annual installments with the first installment vesting on February 27, 2027.
F3 The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.
F4 Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.
F5 The stock option was granted on February 28, 2025, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F6 The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 28, 2025, subject to the Reporting Person's continued service through each applicable vesting date.
F7 The stock option was granted on February 29, 2024, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F8 The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 29, 2024, subject to the Reporting Person's continued service through each applicable vesting date.
F9 The stock option was granted on February 28, 2023, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F10 The stock option is fully vested.

Remarks:

Exhibit 24.1 Power of Attorney